See editorial on page 645.

SummaryIn a mouse model of chronic obstructive pancreatitis, *Kras* mutation in pancreatic ducts led to rapid development of pancreatic ductal adenocarcinoma, whereas *Kras* mutation in acinar cells resulted in growth arrest and no neoplastic changes.

Inflammation plays a pivotal role in cancer initiation and progression in many organs.[@bib1] In the pancreas, chronic pancreatitis (CP) is a predisposing condition for pancreatic ductal adenocarcinoma (PDAC),[@bib2] the most common and deadly cancer of the pancreas, but the link between CP and PDAC is not known. PDAC is usually diagnosed in late-stage disease, leaving little information about how the cancer originated or progressed.

In older people, the presence of *KRAS* mutations in some cells of the healthy pancreas is not uncommon,[@bib3], [@bib4] yet pancreatic cancer remains a relatively rare disease, suggesting that *KRAS* mutation alone is not sufficient for carcinogenesis. Mouse models support this hypothesis. In mice, widespread pancreatic expression of the *Kras*^*G12D*^ mutation alone beginning during embryogenesis leads to PDAC only after long latency,[@bib5] suggesting that other, subsequent events that may be genetic, epigenetic, and/or microenvironmental are required. We found previously that introduction of *Kras*^*G12D*^ expression in CK19+ epithelial cells resulted in neoplastic changes principally in the oral cavity, lungs, and stomach, 3 sites in which damage and inflammation are common.[@bib6] In this work, we directly test whether damage and inflammation in the mouse pancreas can promote *Kras*^*G12D*^-initiated pancreatic cancer, uncovering a mechanism by which inflammation and intrinsic cellular programming synergize for the development of PDAC.

PDAC is a disease of the exocrine pancreas that is composed of 2 predominant tissues, acini that produce zymogens and ducts that transport zymogens to the common bile duct and thence the duodenum. PDAC lesions express a number of ductal markers and have long been thought to arise from a ductal precursor. However, there is evidence from mouse models that acinar cells may be more susceptible than ductal cells to PDAC when tumor suppressor alleles are mutated concomitantly with an activating *Kras* mutation.[@bib7], [@bib8], [@bib9] This is likely due to the ability of acini to undergo a process of acinar-to-ductal metaplasia (ADM) in which they transdifferentiate into ductal cells in response to damage or growth factor signaling.[@bib10], [@bib11], [@bib12] How this etiology relates to the usual pathway of progression of human PDAC is not yet clear.

CP is one of the highest risk factors for human pancreatic cancer,[@bib13] but the underlying mechanism remains obscure. Although all etiologies of CP are not known, many are thought to occur via duct obstruction or defects in duct flow.[@bib14] Therefore, to determine the role of CP arising from duct impairment in pancreatic cancer initiation and progression, we induced duct obstruction in mice carrying an activating *Kras* mutation. Because it remains unclear whether PDAC arises from a ductal or an acinar progenitor cell, we investigated both sources in the setting of CP by using lineage tracing and cell type--specific KRAS^G12D^ induction. We found that chronic obstructive pancreatitis promotes KRAS^G12D^-initiated pancreatic cancer in duct cells but not in acinar cells. Mechanistically, in the context of duct obstruction, KRAS^G12D^ protects both duct and acinar cells from the widespread cell loss that occurs immediately after duct obstruction. Acinar *Kras*^*G12D*^-expressing cells are able to undergo ADM distal to obstruction but up-regulate p53 and its target gene p21, undergoing growth arrest and failing to develop neoplastic changes. In contrast, ductal *Kras*^*G12D*^-expressing cells distal to obstruction lack a p53/p21 response and become proliferative after obstructive CP, leading to a dysplasia-carcinoma sequence of PDAC development.

Results {#sec1}
=======

Obstructive Chronic Pancreatitis Promotes Pancreatic Ductal Adenocarcinoma Development From Ducts but not Acinar Cells Bearing a *Kras^G12D^*Mutation {#sec1.1}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Ductal vs acinar origin of PDAC is unclear, but recent experiments in mice suggest that either cell type can give rise to PDAC if both copies of the *Trp53* gene as well as 1 copy of the *Kras* gene are mutated simultaneously.[@bib7], [@bib9] Whereas acinar cells developed PDAC when only 1 *Trp53* allele was mutated in conjunction with *Kras* mutation, duct cells required both *Trp53* alleles be mutated.[@bib7], [@bib9] However, mutation of *TP53* is thought to occur late in PDAC progression in humans, making it an unlikely initiating event. Because it is well-established in both humans and mice that *Kras* mutation is the initiating event in greater than 90% of PDAC, we compared neoplastic potential between acinar and ductal cells of the pancreas when *Kras* mutation alone was introduced in the setting of chronic obstructive pancreatitis. We introduced *Kras*^*G12D*^ expression using the Cre-inducible *LSL-Kras*^*G12D*^ allele[@bib15] combined with cell type--specific, tamoxifen-inducible CreERT alleles. When recombined, the *LSL-Kras*^*G12D*^ allele expresses mutated *Kras* from the endogenous *Kras* locus. It is important to note that once the *LSL-Kras*^*G12D*^ allele is recombined, all progeny of those cells will carry the activated *Kras*^*G12D*^ allele even if they no longer express any Cre or CreERT protein. The *Ptf1a*^*CreERTM*^ allele[@bib16] was used for inducible expression of *Kras*^*G12D*^ in acinar cells, and the *CK19*^*CreERT2*^ allele[@bib17] was used for inducible expression of *Kras*^*G12D*^ in ductal cells. It is critical to trace the lineage of cells expressing Kras^G12D^ to understand how cancer arises. However, no antibody has thus far been developed that allows detection specifically of Kras^G12D^ mutant protein in tissue sections. One antibody has been reported to distinguish Kras^G12D^ on Western blots but is not recommended for immunohistochemistry by the manufacturer. We tested this antibody on tissue sections and found that it did label metaplastic and dysplastic ducts in mouse pancreas and did not label normal ducts. However, even metaplastic ducts arising in *Kras*^+/+^ mice were labeled by this antibody, indicating that it is not specific to mutant KRAS (data not shown). Because antibodies cannot distinguish wild-type from mutant KRAS mice, the *R26R*^*EYFP*^ reporter allele[@bib18] was bred into mice to label cells that had undergone recombination and therefore were likely to express *Kras*^*G12D*^. *R26R*^*EYFP*^ is an inefficient reporter undergoing recombination at lower rates than other reporters.[@bib19] We found that the *R26R*^*EYFP*^ allele under-reports phenotypes resulting from *LSL-Kras*^*G12D*^ recombination in multiple organs[@bib6] including the pancreas ([Figure 1](#fig1){ref-type="fig"}), in which some pancreatic intraepithelial neoplasm (PanIN) lesions arising in *Ptf1a*^*CreERTM*^ *LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ mice treated with tamoxifen are labeled with EYFP and some are not. Because of the apparent higher efficiency of *LSL-Kras*^*G12D*^ recombination compared with *R26R*^*EYFP*^ recombination, we can be confident that most EYFP+ cells will be KRAS^G12D^+, although a number of EYFP-- cells will also be KRAS^G12D^+. For this reason, we do not compare EYFP+ and EYFP-- cells in the same mouse but rather compare EYFP+ cells in mice with and without the *LSL-Kras*^*G12D*^ allele.Figure 1***Kras* mutant phenotype occurs in EYFP+ and in EYFP-- cells in *Ptf1a***^***CreERTM***^***LSL-Kras***^***G12D***^***R26R***^***EYFP***^**mice, reflecting broader recombination of the *LSL-Kras***^***G12D***^**allele than of the *R26R***^***EYFP***^**allele.** Note the PanIN-like lesions with tall columnar morphology and basal nuclei, some of which are positive for EYFP (*brown*) and some of which are negative (*arrows*).

Mice were administered tamoxifen at 8--10 weeks of age for adult onset expression of *Kras*^*G12D*^. Approximately 4 weeks after tamoxifen administration, CP was induced via duct obstruction by using pancreatic duct ligation (PDL). Tamoxifen was administered at a dose shown to allow CreERT-mediated recombination only up to 1 month after administration because it was shown that higher doses resulted in continued CreERT-mediated recombination 2 months or more after injection.[@bib20] By waiting 4 weeks and using a low dosage of tamoxifen, there would be no tamoxifen-mediated recombination subsequent to PDL. This is critical because when acinar cells undergo ADM, they become ducts and could express duct-specific CreERT alleles if tamoxifen was still available to mediate recombination. This low dose of tamoxifen resulted in 26.4% ± 4.0% of acinar cells labeled with EYFP in *Ptf1a*^*CreERTM*^ *LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ mice and 15.7% ± 2.1% of duct cells labeled in *CK19*^*CreERT2*^ *LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ mice. For PDL, a ligature was placed midway along the main pancreatic duct, allowing the head of the pancreas to remain unaffected while the tail region distal to ligation was subjected to effects of duct obstruction. We have previously shown that PDL results in apoptosis of acini distal to the site of ligation with concomitant inflammation and fibrosis.[@bib16], [@bib21] Mice were followed for up to 4 months after PDL, until *CK19*^*CreERT2*^ *LSL-Kras*^*G12D*^ mice had to be killed because of development of oral papillomas.

Although PDAC tumors have ductal characteristics, acinar cells have been proposed to be the cell of origin[@bib22] through a process of ADM in which acinar cells transdifferentiate into abnormal duct cells.[@bib10], [@bib11], [@bib12] To determine whether acinar cells and ductal cells had different propensities to develop pancreatic cancer in the context of obstructive CP, we compared *Ptf1a*^*CreERTM*^ *LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ (acinar *Kras*^*G12D*^) and *CK19*^*CreERT2*^ *LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ (ductal *Kras*^*G12D*^) mice with control mice with no *Kras*^*G12D*^ expression (*Ptf1a*^*CreERTM*^ *R26R*^*EYFP*^ or *CK19*^*CreERT2*^ *R26R*^*EYFP*^ mice) ([Figure 2](#fig2){ref-type="fig"}). Ten acinar *Kras*^*G12D*^ mice and 4 acinar control mice were all analyzed at 4 months after PDL ([Table 1](#tbl1){ref-type="table"}). Seven ductal *Kras*^*G12D*^ mice and 4 ductal controls were analyzed between 2 and 4 months after PDL, the exact timing depending on oral papilloma development that necessitated euthanasia.Figure 2**Obstructive CP promotes tumorigenesis from duct cells but not from acinar cells.** Mice were subjected to PDL 1 month after tamoxifen treatment and then followed for up to 4 months. (*A--C*) Pancreas distal to ligation (tail region) from mice with no *Kras* mutation (*A*) or *Kras*^*G12D*^ mutation specifically in acinar cells (*B*) or ductal cells (*C*) 4 months after PDL. (*A'*, *B'*, and *C'*) show corresponding pancreata proximal to ligation (head region). (*D*) H&E staining of lesions in *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ mouse 2 months after PDL. Note that no invasion was observed at this time point, but atypia occurred focally. (*E* and *F*) EYFP immunostaining *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ mice showing early invasion. (*G*) Some *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^ lesions have high proliferative index as shown by Ki67 immunohistochemistry (*G*). (*H* and *I*) H&E staining of two *Sox9-CreERT LSL-Kras*^*G12D*^*R26R*^*EYFP*^ distal pancreata showing extensive invasion 8--10 months after PDL. (*J--L*) H&E staining of liver metastatic lesions from *Sox9-CreERT LSL-Kras*^*G12D*^ mouse 10 months after PDL showing low magnification of a large lesion (*J*), a micrometastasis (*K*), and high magnification within a different large metastasis. *Size bars*, 100 μm. met, metastasis; WT, wild-type.Table 1Mice Analyzed 2--10 Months After PDLGenotypeKras^G12D^ expressionSexMo after PDLTail region pathologyIslets in tail*Ptf1a*^*CreERT2*^*R26R*^*EYFP*^Nonef4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*R26R*^*EYFP*^Nonef4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*R26R*^*EYFP*^Nonem4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*R26R*^*EYFP*^Nonem4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarf4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarf4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarf4No ductsYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarf4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarf4No ductsYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarf4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarm4No ductsYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarm4Normal duct epitheliumYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarm4No ductsYes*Ptf1a*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Acinarm4Normal duct epitheliumYes*CK19*^*CreERT2*^*R26R*^*EYFP*^Nonem2Normal duct epitheliumYes*CK19*^*CreERT2*^*R26R*^*EYFP*^Nonef2Normal duct epitheliumYes*CK19*^*CreERT2*^*R26R*^*EYFP*^Nonef2.5Normal duct epitheliumYes*CK19*^*CreERT2*^*R26R*^*EYFP*^Nonef4Normal duct epitheliumYes*CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductf2Focal atypic ductal hyperplasiaYes*CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductf2Focal atypic ductal hyperplasiaYes*CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductm2.5CIS; focal invasionYes*CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductf3CIS; focal invasionYes*CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductm3CIS; focal invasionYes*CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductm4Early PDACYes[a](#tbl1fna){ref-type="table-fn"}*CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductm4Connective tissue onlyNo[a](#tbl1fna){ref-type="table-fn"}*Sox9-CreERT2 R26R*^*EYFP*^Nonem4Normal duct epitheliumYes*Sox9-CreERT2 R26R*^*EYFP*^Nonef8No ductsYes*Sox9-CreERT2 R26R*^*EYFP*^Nonef8Normal duct epitheliumYes*Sox9-CreERT2 R26R*^*EYFP*^Nonem8Normal duct epitheliumYes*Sox9-CreERT2 R26R*^*EYFP*^Nonef10No ductsYes*Sox9-CreERT2 R26R*^*EYFP*^Nonef10Normal duct epitheliumYes*Sox9-CreERT2 LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductm4Connective tissue onlyNo[a](#tbl1fna){ref-type="table-fn"}*Sox9-CreERT2 LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductm4Early invasionYes*Sox9-CreERT2 LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductf8Early PDACYes*Sox9-CreERT2 LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductf8PDAC; liver metastasisYes*Sox9-CreERT2 LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductm8Early PDACYes*Sox9-CreERT2 LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductf10PDACYes[a](#tbl1fna){ref-type="table-fn"}*Sox9-CreERT2 LSL-Kras*^*G12D*^*R26R*^*EYFP*^Ductf8Connective tissue onlyNo[a](#tbl1fna){ref-type="table-fn"}[^2][^3]

By 4 months after PDL, all 8 mice lacking the *LSL-Kras*^*G12D*^ allele completely lost acinar mass but maintained the main pancreatic duct and variable numbers of interlobular and intralobular ducts surrounded by fibrotic and steatotic regions ([Figure 2](#fig2){ref-type="fig"}*A*). In addition, islets and vasculature remained intact distal to ligation (data not shown). The head of the pancreas, proximal to the site of ligation, remained normal ([Figure 2](#fig2){ref-type="fig"}*A'*).

Introduction of *Kras*^*G12D*^ expression into acinar cells of 10 mice followed by PDL resulted in a distal phenotype similar to mice bearing wild-type alleles of *Kras*, with no acinar cells remaining and no dysplastic lesions observed distal to ligation 4 months after PDL ([Figure 2](#fig2){ref-type="fig"}*B*). As in *Kras* wild-type pancreas, remaining distal ducts maintained a low cuboidal epithelium with no apparent cytologic abnormalities. In the head of the pancreas, ADMs and lesions similar to PanINs, thought to be precursors to PDAC, were abundant in acinar *Kras*^*G12D*^ mice by 4 months after PDL, indicating that *Kras*^*G12D*^ recombination occurred efficiently ([Figure 2](#fig2){ref-type="fig"}*B'*). Although it is possible that manipulation occurring during surgery contributed to the abundance of PanIN-like lesions proximal to ligation, these lesions also occur in mice that are not subjected to surgery[@bib23] (data not shown).

When *Kras*^*G12D*^ mutation was introduced into ductal cells of 6 mice, cytologically and architecturally abnormal ductal lesions were found throughout the distal, post-ligation pancreas ([Figure 2](#fig2){ref-type="fig"}*C*) as early as 2 months after tamoxifen. Rare PanIN-like lesions and no ADMs were found in the head of the pancreas of ductal *Kras*^*G12D*^ mice ([Figure 2](#fig2){ref-type="fig"}*C'*) in agreement with previous observations in mice without duct ligation or other insult.[@bib6] Two mice followed for 2 months after PDL developed focal atypic ductal hyperplasia ([Table 1](#tbl1){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}*D*). All ductal *Kras*^*G12D*^ mice that survived to at least 2 months after PDL had cytologic and architectural atypia characteristic of carcinoma in situ in lesions distal to ligation ([Figure 2](#fig2){ref-type="fig"}*D*). Either focally or widespread throughout the distal pancreas, these lesions displayed nuclear hyperchromasia, loss of polarity, and increased nuclear/cytoplasmic ratio. At 2.5--4 months after ligation, varying numbers of lesions showed signs of early invasion with loss of basement membrane integrity and increased stromal cellularity ([Figure 2](#fig2){ref-type="fig"}*C--F*, [Table 1](#tbl1){ref-type="table"}). Invasion was evident by the morphology of the lesions and the presence of small groups of tumor cells, and occasional single cells, located near larger dysplastic lesions, consistent with having emerged from those lesions ([Figure 2](#fig2){ref-type="fig"}*E* and *F*). Many of the benign-appearing lesions were highly proliferative as indicated by Ki67 positivity, whereas regions of carcinoma in situ and early invasion contained sporadic Ki67+ cells ([Figure 2](#fig2){ref-type="fig"}*G*), consistent with invading cells having lower proliferation and highly proliferative cells being less invasive.[@bib24], [@bib25] Thus, in the context of duct obstruction, ductal cells but not acinar cells expressing activated KRAS can undergo neoplasia and progression to dysplasia and local invasion.

Because only one *CK19*^*CreERT2*^ *LSL-Kras*^*G12D*^ mouse could be followed for 4 months (because of development of oral papillomas), we used a second duct-specific CreERT driver, the *Sox9-CreERT2* transgene.[@bib23], [@bib26] *Sox9-CreERT LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ mice were followed for 4, 8, or 10 months after PDL. As seen with the *CK19*^*CreERT2*^ driver allele, six *Sox9-CreERT2 LSL-Kras*^*G12D*^ mice exhibited complete loss of acinar mass distal to ligation, along with carcinoma in situ and early invasion similar to that seen at up to 4 months in *CK19*^*CreERT2*^ *LSL-Kras*^*G12D*^ mice. However, by 8 and 10 months after ligation, lesions were more extensive, and there were larger numbers of invading cells ([Figure 2](#fig2){ref-type="fig"}*H* and *I*, [Table 1](#tbl1){ref-type="table"}). In ductal *Kras*^*G12D*^ mice followed for 4--8 months after PDL, 20%--52% of lobules distal to ligation contained invasive PDAC lesions ([Table 2](#tbl2){ref-type="table"}). In 1 case followed for 10 months, a large tumor engulfed the entire distal region of the pancreas. In this mouse, multiple metastases and micrometastases were found in the liver. The lack of precursor lesions and multiple lesions within the liver and the morphology of tumors were consistent with metastatic PDAC and were likely not cholangiocarcinomas ([Figure 2](#fig2){ref-type="fig"}*J--L*). EYFP is an inefficient reporter not labeling all Kras^G12D^-expressing cells, and the large pancreatic tumor and the liver metastases were all negative for EYFP. Although this does not prove that the metastases derived from this large pancreatic tumor, the data are consistent with this link.Table 2Frequency of Invasive PDAC LesionsSampleCre driverNo. of lobules*%*Mo after PDLWith invasive PDACTotal quantified782-2CK1902502782-3CK1901502764-2CK191362.82.5706-1CK1931812.53791-1CK191173.033709-9CK1962128.94865-2Sox9212204875-3Sox983522.98883-2Sox961452.68886-3Sox93735.78886-2Sox9Tumor 1.5 × 1.2 × 0.7 cm10

Intriguingly, few of the CP-induced lesions in ductal *Kras*^*G12D*^ mice exhibited the classic morphology of PanINs, the best characterized precursors of PDAC. PanINs are characterized, in part, by columnar mucinous cell morphology, often with papillary architecture.[@bib27] In ductal *Kras*^*G12D*^ mice subjected to obstructive CP, lesions with increasing degrees of atypia comprised flat epithelial structures with little papillary or mucinous architecture ([Figure 2](#fig2){ref-type="fig"}*D--I*). In humans, well-differentiated PDAC lesions typically contain cuboidal or low columnar, mucinous cells, similar to PanIN precursors ([Figure 3](#fig3){ref-type="fig"}*A*). However, most human PDAC cases are moderately or poorly differentiated ([Figure 3](#fig3){ref-type="fig"}*B* and *C*), and these lesions with low cuboidal cells containing minimal mucin are morphologically similar to the lesions developing from duct cells in response to CP in our mouse model ([Figure 3](#fig3){ref-type="fig"}*D--F*).Figure 3**Comparison of human and mouse PDAC lesions.** (*A--C*) Human PDAC exhibits a range of morphologies that can be broadly classified as well-differentiated (*A*), moderately differentiated (*B*), and poorly differentiated (*C*). (*D--F*) In the setting of obstructive CP, mouse lesions appear moderately (*D* and *E*) or poorly differentiated (*F*). *Arrows*, cancer cells.

The microenvironment around the dysplastic lesions in mice bore remarkable similarity to that of human PDAC. Collagen fibrils, visualized in blue by trichrome staining, were disorganized around regions of subepithelial invasion but showed the characteristic well-organized, dense parallel bundles around benign lesions ([Figure 4](#fig4){ref-type="fig"}*A*). Alcian blue was used to detect myxoid stroma around some of the dysplastic and invasive lesions ([Figure 4](#fig4){ref-type="fig"}*B*) as well as to show the low frequency of mucin-producing cells in epithelial lesions. As in human PDAC progression, early precursor lesions had little periostin or αSMA+ myofibroblasts surrounding them, with dense, localized accumulation of both occurring as carcinoma in situ developed ([Figure 4](#fig4){ref-type="fig"}*C* and *D*). On the other hand, macrophages were widely distributed throughout and showed characteristic morphologies of infiltrating macrophages in regions of edema and elongated morphologies of murine tissue-resident macrophages surrounding epithelial lesions ([Figure 4](#fig4){ref-type="fig"}*E*). As cancer progressed, myofibroblasts became more widely distributed around regions of extensive invasion ([Figure 4](#fig4){ref-type="fig"}*G* and *H*) as occurs in human PDAC.[@bib28] We also observed that fibronectin becomes reorganized into well-organized parallel fibrils at regions of invasion in human PDAC and in prostate cancer.[@bib29] In both ductal *Kras* models, regions of invading cells were aligned with parallel fibronectin fibrils ([Figure 4](#fig4){ref-type="fig"}*F*).Figure 4**Duct obstruction promotes PDAC with a microenvironment similar to that seen in human PDAC.** All images are distal to ligation. (*A*) *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^ pancreas stained with Gomori's trichrome, which stains fibrillar collagen blue. *Arrowheads*, dense, well-organized collagen bundles not in contact with dysplasia, whereas dysplastic and invasive regions are in contact with poorly organized collagen. (*B*) Alcian blue, pH 2.5, labels myxoid stroma (*bracket*) as well as a small number of ductal lesions (*arrows*). (*C*) Matrix remodeling protein periostin (*brown*) surrounding dysplastic and invasive lesions but scarce surrounding cytologically normal lesions (*upper right corner*). (*D*) Myofibroblasts labeled for αSMA (*brown*) are concentrated around dysplastic and invasive lesions but not cytologically normal lesions. (*E*) Macrophages labeled with F4/80 antibody (*brown*) are widely dispersed throughout distal pancreas. (*F*) Extracellular matrix protein fibronectin (*brown*) forming parallel bundles (*bracket*) around invading cells (*arrowheads*). (*G* and *H*) Macrophages (labeled for F4/80 in *red*) and myofibroblasts (labeled for αSMA in *green*) show the shift in distribution of myofibroblasts from cytologically normal lesions (*G*, *lower right*) with few surrounding myofibroblasts to atypic lesions with increased myofibroblast accumulation (*G*, *upper left*) to widespread distribution in areas of invasion (*H*), whereas macrophages are broadly distributed throughout. (*G'* and *H'*) show αSMA labeling alone. (*G"* and *H"*) show F4/80 alone. *Size bars*, 100 μm.

KRAS^G12D^ Promotes Survival but not Proliferation in Acinar-derived Cells {#sec1.2}
--------------------------------------------------------------------------

To understand how CP promotes KRAS^G12D^-initiated neoplasia in ductal cells but not in acinar cells, we examined an earlier time point at which all genotypes were morphologically similar. At 2 weeks after PDL, all pancreata distal to ligation exhibited comparable fibrosis and loss of acinar mass ([Figure 5](#fig5){ref-type="fig"}*A--F*; data not shown). Numerous ADM-like ductal lesions were present throughout this region regardless of genotype, whereas the head region proximal to ligation remained normal. Previous studies have shown that normal acinar cells undergo p53-dependent apoptosis within a week of duct ligation.[@bib21] To determine whether *Kras*^*G12D*^ mutation protects against this early loss of acinar cells, we compared the relative number of remaining EYFP+ cells at 2 weeks after PDL in mice that were labeled with acinar-specific *Ptf1a*^*CreERTM*^ or duct-specific *CK19*^*CreERT2*^, with and without *Kras*^*G12D*^ mutation, with EYFP serving as a surrogate for *Kras*^*G12D*^ expression as described above. To control for mouse-to-mouse differences in recombination efficiency, we normalized the percentage of EYFP+ cells in the distal affected portion of the pancreas to the percentage of EYFP+ cells in the unaffected head region ([Figure 5](#fig5){ref-type="fig"}*G* and *H*). The rapid, apoptotic loss of acinar cells without *Kras* mutation[@bib21] is reflected in loss of EYFP+ cells in *Ptf1a*^*CreERTM*^ *R26R*^*EYFP*^ pancreas in which there is a 6-fold reduction (0.172% ± 0.053% tail-to-head labeling) in EYFP-labeled cells distal to ligation compared with the unaffected head region of the pancreas ([Figure 5](#fig5){ref-type="fig"}*I*). However, acinar *Kras*^*G12D*^ mice exhibited a 1-to-1 ratio (1.02% ± 0.27% tail-to-head labeling) of labeled cells in the ligated tail compared with the unaffected head region of the pancreas, suggesting that *Kras* mutation protects acinar cells from undergoing early apoptotic loss ([Figure 5](#fig5){ref-type="fig"}*I*).Figure 5**Before morphologic differences, Kras mutation alters the abundance of acinar- and duct-derived cells 2 weeks after duct obstruction.** (*A* and *B*) Gomori's trichrome staining showing fibrillar collagen in blue in *Ptf1a*^*CreERTM*^*Kras*^*G12D*^ (*A*) and in *CK19*^*CreERT2*^*Kras*^*G12D*^ (*B*) mice. (*C*) Percent collagen+ area per genotype showing no statistically significant differences. (*D--F*) Pancreata from 3 different *Ptf1a*^*CreERTM*^*Kras*^*G12D*^ mice showing loss of nearly all amylase staining distal to ligation 2 weeks after PDL. Note positive staining in region proximal to ligation in (*D*). (*G* and *H*) *Ptf1a*^*CreERTM*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ pancreas (*G*) and *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ pancreas (*H*) were labeled for the EYFP protein (*brown*) distal to ligation (tail). (*G'* and *H'*) are corresponding proximal regions (heads) of the pancreata shown in (*G*) and (*H*). (*I*) Quantification of enrichment for EYFP+ (CreERT-activated) cells. Enrichment score is the ratio of the percent of non-endocrine epithelium that is EYFP+ in the tail region to the percent that is EYFP+ in the unaffected head region. (*J*) Similar to (*I*), but only ductal epithelium, not acinar epithelium, was quantified. *Size bars*, 100 μm. \**P* \< .05; \*\**P* \< .01.

Previous work[@bib21] demonstrated that duct cells do not undergo apoptosis after duct ligation. We found that epithelial cells labeled with EYFP expression by *CK19*^*CreERT2*^ but lacking an activating *Kras* mutation were enriched in the tail of the pancreas compared with the unaffected head region (5.61% ± 1.48% tail-to-head labeling; [Figure 5](#fig5){ref-type="fig"}*I*), but this was likely due to loss of acinar cells and therefore enrichment of duct-derived cells. When only duct cells, as opposed to all non-endocrine epithelium, were quantified, there was a reduction of approximately half of the EYFP+ cells without *Kras* mutation (0.461% ± 0.0018% tail-to-head labeling; [Figure 5](#fig5){ref-type="fig"}*J*). Introduction of a *Kras* mutation caused enrichment of duct-derived cells both when comparing total non-endocrine epithelium (17.81% ± 3.19% tail-to-head labeling; [Figure 5](#fig5){ref-type="fig"}*I*) and when comparing only ducts (1.70% ± 0.30% tail-to-head labeling; [Figure 5](#fig5){ref-type="fig"}*J*). Because *Kras* mutation was able to enrich both acinar- and duct-derived cells as well as inducing ADM during the first 2 weeks after duct ligation, we determined whether KRAS^G12D^ had cell type--specific effects subsequent to ADM. Using Ki67 labeling to mark proliferative cells, we found that *Kras*^*G12D*^ mutation resulted in higher proliferation in duct-derived cells compared with acinar-derived cells (19.10% ± 0.75% of EYFP+ cells compared with 3.77% ± 1.13%) ([Figure 6](#fig6){ref-type="fig"}*A--C*). Two weeks after PDL, both acinar-derived and duct-derived *Kras* mutant cells had very low rates of apoptosis as measured by cleaved caspase 3+ cells, and the difference was not statistically significant ([Figure 6](#fig6){ref-type="fig"}*D--F*).Figure 6**Duct-derived cells are more highly proliferative than acinar-derived cells in response to *Kras* mutation distal to duct obstruction.** (*A--C*) *Ptf1a*^*CreERT*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ pancreata (*A*) and *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ pancreata (*B*) were labeled for Ki67 (*red*) and EYFP (*green*) and quantified 2 weeks after PDL for the percent of EYFP+ cells that were also Ki67+ in the affected (distal) region of each pancreas (*C*). (*A'* and *B'*) labeling for Ki67 alone. (*A"* and *B"*) labeling for EYFP alone. (*D--F*) Apoptosis in the same pancreata was quantified for the percent of EYFP+ cells that were also positive for cleaved caspase 3. \**P* \< .05; \*\*\**P* \< .001.

As previously reported, wild-type acinar cells express p53 protein in response to duct obstruction, whereas wild-type ductal cells do not.[@bib21] Expression of Kras^G12D^ did not change this differential response, with high p53 seen widely throughout acinar-derived epithelium but only low or no p53 detected immunohistologically in duct-derived epithelium ([Figure 7](#fig7){ref-type="fig"}*A* and *B*). One target of p53 that could explain the difference in proliferation between acinar-derived and duct-derived *Kras* mutant cells is the cell cycle inhibitor p21. In acinar *Kras*^*G12D*^ mice, 13.86% ± 2.64% of EYFP+ cells were p21-positive, whereas only 1.04% ± 0.61% of EYFP+ cells were p21-positive in ductal Kras^G12D^ mice ([Figure 7](#fig7){ref-type="fig"}*C--E*). No p53 or p21 protein was detected in normal acinar or ductal cells proximal to the site of ligation (data not shown). *Sox9-CreERT2 LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ mice had similar phenotypes to *CK19*^*CreERT2*^ *LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ mice with low levels of p21, p53, and cleaved caspase 3 and high levels of Ki67 ([Figure 8](#fig8){ref-type="fig"}).Figure 7**Mutant *Kras* induces p53 and p21 in acinar-derived but not duct-derived cells distal to duct obstruction.** (*A* and *B*) Immunofluorescent labeling for p53 in *Ptf1a*^*CreERT*^*LSL-Kras*^*G12D*^ cells (*A*) and in *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^ cells (*B*). Images were captured at identical gain and offset. (*C--E*) *Ptf1a*^*CreERT*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ pancreata (*C*) and *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ pancreata (*D*) were quantified (*E*) for the percent of EYFP+ cells that were also p21+ distal to ligation. \**P* \< .05; \*\**P* \< .01.Figure 8***Sox9-CreERT2 LSL-Kras***^***G12D***^***R26R***^***EYFP***^**mice phenocopy *CK19***^***CreERT2***^***LSL-Kras***^***G12D***^***R26R***^***EYFP***^**mice 2 weeks after PDL.** Two *Sox9-CreERT2 LSL-Kras*^*G12D*^ mice were injected with tamoxifen, and PDL was performed as described. Sections were analyzed distal to ligation 2 weeks after PDL for the indicated markers as described in [Figures 6](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}.

Because *Kras* mutation and *Cdkn1a* (encoding p21) expression have been linked to oncogene-induced senescence, we compared senescence-associated β-galactosidase (SA-βgal) activity in acinar-derived and duct-derived *Kras* mutant cells. No SA-βgal activity was seen in either acinar-derived or duct-derived cells with or without *Kras* mutation distal to ligation ([Figure 9](#fig9){ref-type="fig"}*A--C*), although islets showed weak positivity. As a positive control, PanIN-like lesions occurring in the head of pancreata in acinar *Kras*^*G12D*^ mice exhibited SA-βgal activity ([Figure 9](#fig9){ref-type="fig"}*D*) as published.[@bib30], [@bib31]Figure 9***Kras* mutation does not result in oncogene-induced senescence in the setting of obstructive CP.** Cryosections of each genotype were stained for acidic βgal activity (*blue*) as an indicator of oncogene-induced senescence. Tissues shown are *CK19*^*CreERT2*^*R26R*^*EYFP*^ pancreas (*A*), *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ pancreas (*B*), and *Ptf1a*^*CreERT*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ pancreas (*C*) each at 2 weeks after PDL. (*D*) PanIN-like lesions in the head of the pancreas of *Ptf1a*^*CreERT*^*LSL-Kras*^*G12D*^*R26R*^*EYFP*^ mice 4 months after PDL. *i*, islet. *Size bars*, 100 μm.

The reduced proliferation of acinar-derived compared with duct-derived KRAS^G12D^+ cells suggests that acinar cells may not give rise to tumors in the setting of CP because the cells are eliminated over time. To test this possibility, we determined whether EYFP+ cells remained 2--4 months after ligation. Indeed, in both *Ptfa1*^*CreERTM*^ *R26R*^*EYFP*^ mice and *Ptfa1*^*CreERTM*^ *LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ mice that had undergone tamoxifen injection and PDL, we found that some mice no longer contained EYFP+ acinar-derived cells distal to ligation, whereas all *CK19*^*CreERT2*^ *R26R*^*EYFP*^ and *CK19*^*CreERT2*^ *LSL-Kras*^*G12D*^ *R26R*^*EYFP*^ mice retained EYFP+ duct-derived cells. However, with or without *Kras* mutation, acinar-derived cells were retained 4 months after PDL in some mice. In 2 of 4 of the *Kras*^*+/+*^ mice, acinar-derived EYFP+ cells comprised 6.7% and 9.8% of epithelial cells distal to ligation ([Figure 10](#fig10){ref-type="fig"}*A*). In 3 of 5 acinar *Kras*^*G12D*^ mice retaining EYFP+ cells, 54.9% ± 8.4% of distal epithelial cells were EYFP+. In ductal control mice, 16.0% ± 2.3% of distal epithelium was EYFP+, and in ductal *Kras*^*G12D*^ mice, 52.0% ± 6.4% was EYFP+, indicating an enrichment with mutant KRAS in cells of ductal origin (*P* \< .01). Remaining acinar-derived as well as duct-derived EYFP+ cells were variably proliferative regardless of *Kras* status ([Figure 10](#fig10){ref-type="fig"}*B*). This may be in response to occurrence of areas of delamination in some distended ducts ([Figure 10](#fig10){ref-type="fig"}*C*). However, p21 was significantly more prevalent in acinar-derived EYFP+ cells ([Figure 10](#fig10){ref-type="fig"}*D--G*).Figure 10**Up to 4 months after PDL, many remaining lesions have recombined cells and varying degrees of proliferation.** (*A*) Two to 4 months after PDL, recombined cells as measured by EYFP were still present in lesions from some acinar control and acinar *Kras*^*G12D*^ mice and in all duct-derived control and *Kras*^*G12D*^ pancreata. (*B*) Both acinar-derived and duct-derived lesions exhibited varying levels of proliferation. (*C*) Many dilated lesions of all genotypes exhibited loss of epithelial integrity associated with inflammatory infiltrates distal to ligation. Image shown is *Ptf1a*^*CreERT*^*LSL-Kras*^*G12D*^ pancreas 4 months after obstruction. (*D*) Acinar-derived lesions continued to express p21 at a much higher level than did duct-derived lesions. *Squares with white centers* correspond to *Sox9-CreERT2 LSL-Kras*^*G12D*^ mice, and *solid black squares* correspond to *CK19*^*CreERT2*^*LSL-Kras*^*G12D*^ mice. (*E--G*) Images showing p21 (*red*) and EYFP (*green*) in acinar control (*E*), acinar *Kras*^*G12D*^ (*F*), and duct *Kras*^*G12D*^ (*G*). p21 alone is shown in corresponding images below (*E'--G'*). \**P* \< .05; \*\**P* \< .01; \*\*\**P* \< .001.

Discussion {#sec2}
==========

The work presented here indicates that obstructive CP is a potent promoter of PDAC, suggesting that the local tissue microenvironment plays a major regulatory role in PDAC development. In studies of adult mouse pancreas, expression of *Kras*^*G12D*^ from the endogenous *Kras* locus does not lead to carcinoma unless a tumor suppressor such as *Trp53* and/or *Fbw7* is also mutated.[@bib7], [@bib8], [@bib9] However, with *Kras*^*G12D*^ expression in ducts, CP led to neoplastic changes including carcinoma in situ by 2 months. Focal areas of invasion were observed between 2.5 and 3 months, with widespread invasion by 4 months after obstruction. This rapid development of pancreatic cancer supports previous studies that invasion happens at a relatively early stage of PDAC development.[@bib32] Furthermore, PDAC lesions developed within a dynamic microenvironment that recapitulated that seen in the development of human PDAC.[@bib28] This microenvironment includes a gradual transition in accumulation of myofibroblasts and periostin protein as lesions progress from benign to malignant, whereas macrophages are prevalent throughout this transition.

*KRAS* is mutated in \>90% of human PDAC tumors. Studies of human tissues and mouse models indicate that it acts as a cancer initiator that relies on other events to promote tumor development. We found in previous studies that effects of *Kras* mutation are very context-dependent in vivo, with tissues most exposed to environmental damage (oral cavity, lungs, and stomach) being much more susceptible to neoplasia than are the less exposed liver, kidney, and pancreas tissues.[@bib6] Here we have uncovered one mechanism by which damage and associated inflammation may promote transformation in some cells while preventing transformation in other cells. Obstructive CP induces apoptosis via p53 induction in acinar cells but not duct cells of the pancreas.[@bib21] We found that *Kras* mutation does not block p53 induction in acinar cells after obstructive CP but does block the early loss of acinar cells after duct obstruction, thus bypassing one of the functions of p53. Because loss of acinar cells was shown to result from p53-dependent apoptosis in *Kras*^*+/+*^ mice,[@bib21] the *Kras*^*G12D*^-dependent enrichment of acinar cells is likely due to decreased apoptosis. However, we cannot rule out that there is also a transient burst of proliferation during the first 2 weeks after duct obstruction. Despite protecting acinar-derived cells from early loss, induction of p53 and its target gene *Cdkn1a*, encoding the cell cycle inhibitor p21, correlated with decreased proliferation of acinar-derived cells even though they express *Kras*^*G12D*^. Ductal cells do not undergo p53 or p21 induction after duct obstruction and thus rapidly proliferate in response to *Kras*^*G12D*^ expression. This proliferation then allows cell expansion and eventual neoplasia. Thus, one determinant of the ability of the *Kras*^*G12D*^ mutation to initiate carcinogenesis may be whether the cells undergo a robust p53/p21 response.

In some mice, reduced proliferation in acinar-derived, *Kras*-mutated cells was associated with loss of these cells over time, and this may be one of the mechanisms by which acinar cells are less susceptible to carcinogenesis in the setting of obstructive CP. However, some acinar-derived mutant cells escaped this selection and were maintained up to 4 months after PDL. Although many of these cells continue to express p21, some cells become proliferative, perhaps in response to duct dilation and resultant loss of epithelial integrity. It is possible that these remaining mutant cells could, over time, acquire mutation of *Trp53* or other tumor suppressor genes that would then lead to carcinogenesis. This would be consistent with data in the field that mutation of *Trp53* in conjunction with *Kras* mutation rapidly leads to acinar-derived PDAC, whereas *Kras* mutation alone does not.[@bib7], [@bib9] Our mouse model of acinar *Kras* mutation relies on loss of one *Ptf1a* allele, and this may also contribute to the inability of acinar-derived cells to undergo tumorigenesis. However, work from others indicates that loss of *Ptf1a* makes acinar cells more susceptible, not less susceptible, to tumorigenesis.[@bib33], [@bib34] It is also unlikely that differences in Cre-mediated recombination in our acinar-derived and duct-derived cell models are responsible for the differences in carcinogenesis. Slightly higher percentages of acinar cells underwent Cre-mediated recombination, and there are many more acinar cells than duct cells in the pancreas, yet acinar cells were unable to undergo neoplastic changes. Another caveat to these experiments is that we are inducing CP and PDAC in the tail of the pancreas, whereas humans develop PDAC in the head of the pancreas in 60%--70% of cases.[@bib35]

Our results and the work of others[@bib8], [@bib21], [@bib23] indicate that the 2 principal cells of the exocrine pancreas, acinar cells and duct cells, have variable responses to oncogenic and inflammatory stimuli. In terms of inflammatory responses, most prior work has studied the inflammatory response to cerulein, a cholecystokinin (CCK) analog that binds CCK receptors on mouse acinar cells and supraphysiologically stimulates zymogen secretion, provoking inflammation and ADM that gradually resolve when treatment is stopped.[@bib12] In the presence of mutant *Kras*, these ADM lesions gain a PanIN-like morphology and are maintained as such after cerulein administration has stopped.[@bib36] In *Kras* mutant mouse models, the high occurrence of acinar-derived PanIN-like lesions and low occurrence of duct-derived PanIN-like lesions in the presence of cerulein led to the conclusion that acinar cells are the most likely source of PDAC.[@bib23] However, cerulein does not directly target duct cells and does not appear to promote neoplastic events in duct cells.[@bib23] In addition, the cerulein-induced inflammation models are likely irrelevant to human disease because human acinar cells lack CCK receptors and are unresponsive to cerulein.[@bib37] Our obstructive CP model affects both acinar and ductal cells and models a common etiology of human CP. From this etiology, *Kras* mutation in duct cells but not in acinar cells was able to induce PDAC. Although introducing a *Kras* mutation embryonically allows PDAC to develop at \>6 months of age in the FVB/N background[@bib5] and \>10 months in C57BL/6J (data not shown), no other model has shown that adult-onset endogenously controlled expression of *Kras*^*G12D*^ without further genetic modification is sufficient for PDAC development. In the setting of obstructive CP, we show that there is a clear difference in response of acinar cells and duct cells to *Kras* mutation. Whereas the susceptibility to PDAC was confined to cells of ductal origin distal to duct obstruction, PanIN-like lesions developed and appeared to be maintained in the head of the pancreata of acinar Kras^G12D^ mice. Although these lesions occur even without surgical manipulation, we cannot rule out that the inflammation induced by duct ligation had an effect on the timing or abundance of these lesions.

The PDAC lesions developing in the context of obstructive CP did not appear to proceed through the classic PanIN series. Rather than columnar, mucinous precursor cells, benign lesions had low cuboidal cells ("flat" morphology) even as they exhibited increasing cellular atypia. Carcinoma in situ lesions showed extensive dysplasia, and the cancer itself was moderately to poorly differentiated. In humans, PDAC tumors show variable morphologies, some with well-differentiated ductal structures with columnar mucinous cells, whereas others consist of scattered clusters of moderately or poorly differentiated cells that may or may not be mucinous. These different morphologies may reflect different cells of origin. In a recent report, Lee et al[@bib9] found that acinar-derived tumors arising from *Kras*^*G12D*^ mutation combined with targeted deletion of *Trp53* (*Ptf1a*^*CreERT*^ *LSL-Kras*^*G12D*^ *Trp53*^*fl/fl*^ mice) resulted in more frequent mucinous lesions than occurred in *Sox9-CreERT LSL-Kras*^*G12D*^ *Trp53*^*fl/fl*^ mice. Indeed, it has become appreciated that intraductal papillary mucinous neoplasm, once thought to be a separate and usually benign neoplasm, can be a precursor to PDAC.[@bib38] It has recently been suggested that atypical flat lesions, similar to those we see in our mouse model of CP-promoted PDAC, can also be precursors for human PDAC.[@bib39], [@bib40] It is plausible that the differing morphologies of PDAC result from different etiologies with different types of precursor lesions.

Materials and Methods {#sec3}
=====================

Mice {#sec3.1}
----

*Ptf1a*^*CreERTM*^,[@bib16] *CK19*^*CreERT2*^,[@bib17] *Sox9-CreERT2*,[@bib23] *LSL-Kras*^*G12D*^,[@bib15] and *R26R*^*EYFP*^ [@bib18] mice have been described previously. Cre-mediated recombination was performed at 8--12 weeks of age, with 3 intraperitoneal injections of 2.0 mg tamoxifen, once daily on alternating days (days 1, 3, and 5). One month later, PDL was performed as described,[@bib16] suturing around the main pancreatic duct in the body of the pancreas where the parenchyma narrows before again widening. Mice were allowed to recover and were followed for the times indicated. Two mice were excluded from the studies (but shown in [Table 1](#tbl1){ref-type="table"}) because of loss of all exocrine and endocrine tissue distal to ligation with only a small amount of connective tissue remaining, suggesting that necrosis may have occurred. All mouse procedures were approved by the Vanderbilt Institutional Animal Care and Use Committee.

Histology {#sec3.2}
---------

Tissues were fixed in 4% paraformaldehyde, washed, then either cryopreserved or dehydrated and paraffin embedded. Sections were cut at a depth of 5 μm. For immunohistologic analyses, slides were deparaffinized and washed, and antigens were retrieved in 10 mmol/L sodium citrate, pH 6 for all except the GFP antibody, which was retrieved in 100 mmol/L Tris, pH 10. Retrieval was done in a pressure cooker (Cuisinart, Stamford, CT) set on high pressure for 15 minutes but left heating for 1 hour. Tissues were quenched in 3% hydrogen peroxide and then washed and blocked in phosphate-buffered saline + 5% normal goat or donkey serum + 1% bovine serum albumin. Slides were then incubated in the indicated antibody overnight at 4°C, detected with biotin-labeled secondary antibody and avidin-biotin amplification using Vector ABC Elite kits (Vector Laboratories, Burlingame, CA) and 3,3′-diaminobenzidine substrate (Vector Laboratories) according to manufacturer's recommendation, and then counterstained with hematoxylin (Fisher Scientific, Pittsburgh, PA). Double immunofluorescence was performed by using TSA-plus kits (Perkin Elmer LAS, Boston, MA) according to manufacturer's protocol except the tyramide reagent was diluted 1:1000 and counterstained with Toto3 (Molecular Probes, Eugene, OR). Antibodies used were rabbit anti-GFP (EYFP) (Novus Biologicals, Centennial, CO), mouse anti-αSMA (clone 1A4; Dako, Carpinteria, CA), rabbit anti-periostin (Abcam, Cambridge, England), rabbit anti-cleaved caspase 3 (Cell Signaling Technology, Boston, MA), rabbit anti-Ki67 (Abcam), rabbit anti-p53 (Novocastra Laboratories, Newcastle upon Tyne, UK), rabbit anti-p21(Abcam), goat anti-amylase (Santa Cruz Technology, Santa Cruz, CA), and rabbit anti-Kras^G12D^ (Cell Signaling). SA-βgal activity on cryosections was done as published.[@bib41] Brightfield images were captured on an Axioskop40 microscope using an Axiocam MRC camera (Zeiss, Jena, Germany) except images in [Figure 3](#fig3){ref-type="fig"}, which were captured on a BX41 microscope using a U-CAM3 camera (Olympus, Center Valley, PA). Fluorescent images were captured on an LSM 510 META inverted confocal microscope (Zeiss).

Statistical Analyses {#sec3.3}
--------------------

Trichrome analysis was performed in the Digital Histology Shared Resource at Vanderbilt University Medical Center. Trichrome images were captured by using a high throughput SCN400 Slide Scanner (Leica Microsystems, Buffalo Grove, IL) and analyzed by the Tissue Image Analysis 2 software (Leica). Graphs were made and analyzed by using Prism (Graphpad, San Diego, CA). Student *t* tests were used to analyze labeled cell numbers between different genotypes. Numbers of mice analyzed are indicated in tables and by data points in graphs.
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